Literature DB >> 11939923

Remifentanil sedation compared with propofol during regional anaesthesia.

F S Servin1, J C Raeder, J C Merle, M Wattwil, A L Hanson, M H Lauwers, A Aitkenhead, J Marty, K Reite, S Martisson, L Wostyn.   

Abstract

BACKGROUND: The short onset and offset of remifentanil may allow for accurate dosing of sedative effect with few side-effects and rapid recovery. In this study remifentanil is compared with propofol for sedation during successful regional anaesthetic blocks.
METHODS: After informed consent was given, 125 patients undergoing surgery under spinal or brachial plexus anaesthesia were randomized to receive, either propofol: bolus 500 microg/kg plus initial infusion 50 microgkg/min or remifentanil: bolus 0.5 microg/kg plus initial infusion 0.1 microgkg/min. Study drug infusion rate was titrated throughout the procedure according to level of sedation and side-effects. Pain, discomfort, sedation level and side-effects were recorded at regular intervals until discharge from the post operative care unit (PACU).
RESULTS: Two patients in the remifentanil group versus ten in the propofol group were treated for discomfort or pain during surgery (P<0.02). Due to a significantly higher rate of respiratory depression (46% vs. 19% with propofol, P<0.01) the mean remifentanil infusion rate was decreased to 0.078 +/- 0.028 microgkg/min, whereas it was kept stable with propofol. Propofol patients had significantly higher (P<0.05) sedation levels and experienced more frequent amnesia of the procedure. Eleven propofol patients experienced pain at injection site, versus two remifentanil patients (P<0.02). Nausea and vomiting were more frequent in the remifentanil patients during infusion (27% vs. 2% in the propofol group, P<0.001) but similar postoperatively. Time to discharge from PACU was similar in the two groups.
CONCLUSION: Propofol results in less respiratory depression and nausea when sedation is needed during a case with a successful regional block. Remifentanil may be considered as an alternative if pain during the procedure is a major concern or if amnesia is contraindicated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11939923     DOI: 10.1034/j.1399-6576.2002.t01-1-460314.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  7 in total

Review 1.  Remifentanil update: clinical science and utility.

Authors:  Richard Beers; Enrico Camporesi
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

2.  Target-controlled infusion of remifentanil for conscious sedation during spinal anesthesia.

Authors:  Sung Hye Byun; Doo Youn Hwang; Seong Wook Hong; Si Oh Kim
Journal:  Korean J Anesthesiol       Date:  2011-09-23

3.  Comparison of dexmedetomidine and remifentanil infusion in geriatric patients undergoing outpatient cataract surgery: a prospective, randomized, and blinded study.

Authors:  Cem Kaya; Nalan Ornek Celebi; Sehend Debbag; Ozgur Canbay; Ozkan Onal
Journal:  Med Gas Res       Date:  2022 Oct-Dec

4.  Comparison of clinical safety and efficacy of dexmedetomidine, remifentanil, and propofol in patients who cannot tolerate non-invasive mechanical ventilation: A prospective, randomized, cohort study.

Authors:  Mine Altınkaya Çavuş; Serife Gökbulut Bektaş; Sema Turan
Journal:  Front Med (Lausanne)       Date:  2022-08-30

5.  Review of the efficacy and safety of remifentanil for the prevention and treatment of pain during and after procedures and surgery.

Authors:  Erica L Sivak; Peter J Davis
Journal:  Local Reg Anesth       Date:  2010-07-15

6.  Comparing remifentanil versus propofol effect on pain and homodynamic change of patients undergoing phacoemulsification with topical anesthesia.

Authors:  Dawood Aghadoost; Mohammad Reza Fazel; Esmaiel Fakharian
Journal:  Iran Red Crescent Med J       Date:  2013-05-05       Impact factor: 0.611

7.  A phenome-guided drug repositioning through a latent variable model.

Authors:  Halil Bisgin; Zhichao Liu; Hong Fang; Reagan Kelly; Xiaowei Xu; Weida Tong
Journal:  BMC Bioinformatics       Date:  2014-08-08       Impact factor: 3.169

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.